Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2020-07-27
2022-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prophylactic Amnioinfusion for Prevention of Postpartum Hemorrhage
NCT06691945
Evaluation of the Hem-Avert® Perianal Stabilizer Into Routine Clinical Practice
NCT02562547
Prevention of Post-partum Haemorrhage
NCT01044082
N-acetylcysteine in Intra-amniotic Infection/Inflammation
NCT00397735
Oxytocin Administration in the Third Stage of Labour - A Study of Appropriate Route and Dose
NCT00200252
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ROTEM - rotation thromboelastometry testing
The ROTEM® is a simple blood test that provides information about specific components involved in blood clotting and stopping hemorrhage.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Gestational age ≥ 34 weeks
3. ≥ 1 High-risk of postpartum hemorrhage criteria defined as either of:
1. Nulliparous women admitted for induction of labor with unfavorable cervix (Bishop's score \<5)
2. Prior uterine surgery (\> 1 prior cesarean or myomectomy)
3. Patients undergoing trial of labor after cesarean delivery
4. History of postpartum hemorrhage
5. ≥4 previous vaginal deliveries
6. Multiple gestation
7. The presence of \> 2 uterine fibroids or fibroid \> 5 cm on any ultrasound during the pregnancy
8. Planned magnesium sulfate use
9. Placenta previa/accreta/increta/percreta
Exclusion Criteria
2. Antepartum hemorrhage present on admission (\>500cc Estimated Blood Loss (EBL))
3. Coagulation defects
4. Thrombocytopenia with platelets count \<100,000
5. Enrolled in the "Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean (TXA)" (NCT03364491) study or planned receipt of Tranexamic Acid (TXA) prior to enrollment.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ohio State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael Cackovic
MD, Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020H0119
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.